The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Revenue from operations climbed 13% to Rs. 886.87 crore
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The approval was granted by Agenzia Italiana del Farmaco
Transition to a fermentation-based globally integrated CDMO platform
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Subscribe To Our Newsletter & Stay Updated
